EUVIMEDEUVIMED entdecken
Crossref

Identification and validation of the TRHDE‐AS1 / hsa‐miR ‐449a/ ADAMTS5 axis as a novel prognostic biomarker in prostate cancer

Xin Lian, Honglan Zhou, Si Liu iD

BioFactors · 2024-11 · 50 (6) · 1251-1267

DOI: 10.1002/biof.2083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, online erschienen am 31.05.2024. Verfasst von Xin Lian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, MicroRNAs, Biomarkers, Tumor, RNA, Long Noncoding. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: the Natural Science Foundation of Jilin Province, Natural Science Foundation of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advancements in cancer research, the prognostic implications of competing endogenous RNA (ceRNA) networks in prostate cancer (PCa) remain incompletely understood. This study aimed to elucidate the prognostic relevance of ceRNA networks in PCa, utilizing a comprehensive bioinformatics approach alongside experimental validation. After searching The Cancer Genome Atlas (TCGA) database, RNA sequencing (RNA‐Seq) data were extracted to identify differentially expressed RNAs (DERs) between 491 PCa samples and 51 normal prostate tissues, following which a comprehensive bioinformatics strategy was implemented to construct a ceRNA network. An optimal prognostic signature comprising these DERs was then established and validated using TCGA data. In addition, functional validation was performed through RNA pull‐down, dual‐luciferase reporter assays, quantitative real‐time PCR, and western blot analysis conducted in PC‐3 and DU145 cell lines, thereby complementing the bioinformatics analysis. A total of 613 DERs, comprising 103 long noncoding RNAs (lncRNAs), 60 microRNAs (miRNAs), and 450 messenger RNAs (mRNAs), were identified and utilized in constructing a ceRNA network, which encompassed 23 lncRNAs, 9 miRNAs, and 52 mRNAs. An optimal prognostic signature was established, including VPS9D1 antisense RNA 1 (VPS9D1‐AS1), miR‐449a, cyclin‐dependent kinase 5 regulatory subunit 1 (CDK5R1), targeting protein for Xklp2 (TPX2), solute carrier family 7 member 11 (SLC7A11), copine7 (CPNE7), and maternal embryonic leucine zipper kinase (MELK), yielding area under the curve (AUC) values exceeding 0.8 across training, validation, and entire datasets. Our experiments results revealed an interaction between lncRNA TRHDE antisense RNA 1 (TRHDE‐AS1) and miR‐449a and that miR‐449a could target the ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) mRNA. Knockdown of miR‐449a significantly impeded cell proliferation, G1/S transition, migration and invasion, and promoted apoptosis in PC‐3 and DU145 cells. Furthermore, knockdown of miR‐449a notably downregulated protein expression of CDK4, cyclin D1, N‐cadherin and vimentin, while upregulating protein expression of cleaved caspase‐3 and E‐cadherin. This study contributes to a deeper understanding of the prognostic‐linked ceRNA network in PCa, providing fundamental insights that could improve diagnostic and therapeutic approaches for PCa management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMicroRNAsBiomarkers, TumorRNA, Long NoncodingGene Expression Regulation, NeoplasticHumansMalePrognosisCell Line, TumorCell ProliferationComputational BiologyGene Regulatory NetworksCell MovementApoptosis

Stichwörter der Autor:innen

competing endogenous RNA networkmiR‐449aprognosisprostate cancer

Substanzen

MicroRNAsBiomarkers, TumorRNA, Long NoncodingMIRN449 microRNA, human

Autor:innen und Institutionen

  • Department of Urology, The First Hospital of Jilin University, Changchun, China.

ORCID-Profile: Si Liu

Förderung

  • the Natural Science Foundation of Jilin Province
  • Natural Science Foundation of Jilin Province

Zitieren

APA

Lian, X., Zhou, H., & Liu, S. (2024). Identification and validation of the TRHDE‐AS1 / hsa‐miR ‐449a/ ADAMTS5 axis as a novel prognostic biomarker in prostate cancer. BioFactors, 50(6), 1251-1267. https://doi.org/10.1002/biof.2083

Vancouver

Lian X, Zhou H, Liu S. Identification and validation of the TRHDE‐AS1 / hsa‐miR ‐449a/ ADAMTS5 axis as a novel prognostic biomarker in prostate cancer. BioFactors. 2024;50(6):1251-1267. doi:10.1002/biof.2083

BibTeX
@article{Lian2024,
  author = {Lian, Xin and Zhou, Honglan and Liu, Si},
  title = {Identification and validation of the TRHDE‐AS1 / hsa‐miR ‐449a/ ADAMTS5 axis as a novel prognostic biomarker in prostate cancer},
  journal = {BioFactors},
  year = {2024},
  volume = {50},
  number = {6},
  pages = {1251--1267},
  doi = {10.1002/biof.2083}
}
Kostenlos starten →